Advantage Alpha Capital Partners LP Buys New Holdings in Krystal Biotech, Inc. $KRYS

Advantage Alpha Capital Partners LP bought a new stake in Krystal Biotech, Inc. (NASDAQ:KRYS) in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 3,569 shares of the company’s stock, valued at approximately $643,000.

Several other hedge funds have also recently bought and sold shares of the stock. Price T Rowe Associates Inc. MD lifted its position in Krystal Biotech by 16.2% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 509,459 shares of the company’s stock worth $79,812,000 after acquiring an additional 71,200 shares during the last quarter. Soleus Capital Management L.P. lifted its position in Krystal Biotech by 65.2% during the fourth quarter. Soleus Capital Management L.P. now owns 358,379 shares of the company’s stock worth $56,144,000 after acquiring an additional 141,400 shares during the last quarter. Northern Trust Corp lifted its position in Krystal Biotech by 9.9% during the fourth quarter. Northern Trust Corp now owns 262,263 shares of the company’s stock worth $41,086,000 after acquiring an additional 23,572 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its position in Krystal Biotech by 3.0% during the first quarter. Charles Schwab Investment Management Inc. now owns 250,514 shares of the company’s stock worth $45,168,000 after acquiring an additional 7,344 shares during the last quarter. Finally, Nuveen LLC acquired a new stake in Krystal Biotech during the first quarter worth approximately $42,223,000. 86.29% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities research analysts have issued reports on KRYS shares. Bank of America cut their price objective on shares of Krystal Biotech from $193.00 to $192.00 and set a “buy” rating for the company in a research report on Tuesday, July 22nd. Guggenheim lowered their target price on shares of Krystal Biotech from $195.00 to $189.00 and set a “buy” rating on the stock in a report on Wednesday, May 7th. Chardan Capital reaffirmed a “buy” rating and set a $219.00 target price on shares of Krystal Biotech in a report on Tuesday, August 5th. Citigroup reaffirmed a “neutral” rating and set a $166.00 target price (down from $176.00) on shares of Krystal Biotech in a report on Tuesday, August 5th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $240.00 target price on shares of Krystal Biotech in a report on Friday, July 25th. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average target price of $210.75.

Insider Transactions at Krystal Biotech

In related news, insider Suma Krishnan sold 13,435 shares of Krystal Biotech stock in a transaction that occurred on Monday, July 14th. The shares were sold at an average price of $150.30, for a total value of $2,019,280.50. Following the transaction, the insider directly owned 1,443,276 shares of the company’s stock, valued at $216,924,382.80. This trade represents a 0.92% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Insiders have sold 49,800 shares of company stock valued at $7,487,943 over the last quarter. Company insiders own 13.70% of the company’s stock.

Krystal Biotech Price Performance

Shares of NASDAQ:KRYS opened at $145.70 on Friday. The company’s 50 day simple moving average is $143.96 and its 200 day simple moving average is $154.67. The stock has a market capitalization of $4.22 billion, a price-to-earnings ratio of 29.61 and a beta of 0.70. Krystal Biotech, Inc. has a 1 year low of $122.80 and a 1 year high of $207.84.

Krystal Biotech (NASDAQ:KRYS) last announced its quarterly earnings data on Monday, August 4th. The company reported $1.29 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.08 by $0.21. The business had revenue of $96.04 million for the quarter, compared to analysts’ expectations of $95.42 million. Krystal Biotech had a net margin of 40.85% and a return on equity of 15.21%. As a group, analysts anticipate that Krystal Biotech, Inc. will post 6.14 EPS for the current fiscal year.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).